Fact CheckerSign in

NCT06971874Recruiting

The Outcome of Chronic Kidney Disease Patients With Obstructive Sleep Apnea Syndrome

The Epidemiological Patterns of Obstructive Sleep Apnea Syndrome in Patients With Chronic Kidney Disease and Its Impact on Renal Prognosis

Source: ClinicalTrials.gov · Last updated 17 Nov 2025

Brief summary (registry, in English)

Obstructive sleep apnea (OSA) is highly prevalent in chronic kidney disease (CKD) patients and strongly linked to obesity, metabolic syndrome, and type 2 diabetes. Besides elevating cardiovascular disease risk, OSA may worsen renal function and diminish quality of life, making its understanding critical for CKD patient health. This study will establish a large, long-term cohort of non-dialysis CKD patients to identify OSA risk factors, explore OSA's association with adverse renal outcomes, and determine OSA prevalence and epidemiological characteristics within the CKD population. The findings will provide a scientific foundation for early OSA identification, diagnosis, and intervention in CKD patients.

Status (registry)
Recruiting
Study type
Observational
Enrollment
356 (estimated)
First submitted
20 Mar 2025
Start date
Jul 2025
Primary completion date
Jun 2029
Lead sponsor
Nanfang Hospital, Southern Medical University
NCT number
NCT06971874

What you commit to

  • Study type: Observational
  • Planned participants: 356
  • From Jul 2025 to the primary completion date, Jun 2029
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Patients receiving oxygen therapy or continuous positive airway pressure (CPAP) treatment;
    • Patients with other sleep disorders, including restless legs syndrome, periodic limb movement disorder, etc.;
    • Patients with other severe comorbidities: Severe heart failure (NYHA class III or IV); Myocardial infarction, unstable angina, or stroke within the past 3 months; Severe arrhythmias requiring medication or device therapy; Respiratory diseases, including COPD, asthma, thoracic deformities, etc.; Neurological disorders, including myasthenia gravis, Parkinson's disease, Alzheimer's disease, etc.; Active liver disease or severe hepatic insufficiency; Psychiatric conditions, including depression, anxiety disorders, etc.; History of malignancy within the past 5 years (except cured basal cell carcinoma); Uncontrolled hyperthyroidism;
    • Patients who underwent surgery or had acute infections within the past 3 months;
    • Current heavy alcohol consumption:Females: \>3 drinks/day or \>7 drinks/week; Males: \>4 drinks/day or \>14 drinks/week (1 standard drink = 14g of alcohol)
    • Current use of medications that may severely interfere with sleep, such as antipsychotics, antiepileptics, antiparkinsonian drugs, antidepressants, opioids, etc.;
    • Females who are pregnant or lactating at screening or baseline;
    • Inability to comply with the study due to: Low education level, language barriers, inability to tolerate or complete sleep monitoring, or other reasons preventing completion of study procedures (e.g., follow-up);
    • Deemed unsuitable for participation by the investigator's judgment.

Who the study is looking for

  • Voluntarily sign the informed consent form;
    • Aged ≥ 18 years and \< 75 years;
    • Patients with CKD stages 3-4, with an eGFR of 15-60 ml/min/1.73m² calculated using the CKD-EPI formula for at least 3 months.

Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Nanfang Hospital, Southern Medical University
Coordinator of this site? Confirm its status
GuangzhouChinaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.